

INSULIN ALERT

A HIGH strength insulin glargine is PBS listed. Toujeo® is **THREE** times more concentrated than Lantus®. Patients using it may be admitted to your hospital.



Insulin Glargine (Toujeo®) - 300 units/mL



Insulin Glargine (Lantus®) - 100 units/mL

If a patient is admitted on Toujeo® :

- Toujeo® 300 units/mL insulin must **NEVER** be drawn up into a U-100 insulin syringe. This will cause THREE (3) times the amount of insulin to be administered.



- Patient able to self-administer: Toujeo® 300 units/mL can be continued.
- Patient unable to self-administer: Cease Toujeo® and prescribe Lantus® 100 units/mL. Consider a 20% dose reduction (*e.g. if on Toujeo® 80 units, reduce dose by 20% (16 units) to Lantus® 64 units*). The Lantus® dose should be drawn up from a 3 mL insulin cartridge and administered using an insulin syringe. Continue to monitor blood glucose QID and titrate to target.
- Patient regains the ability to self-administer: Cease Lantus® and recommence Toujeo® at a 1 to 1 unit dose ratio (*e.g. if Lantus® is 34units, the Toujeo® dose is 34 units*). Continue to monitor blood glucose QID and titrate to target.

For patients self-administering any insulin, use the Auto Shield Duo 30G X 5mm safety pen needles with a pen device. Order via Oracle 15004420 (100 per box).



See SA Health [Medication Safety Notice No. SA 01/18](#) for further information.

For additional support please consult your clinical pharmacist, credentialed diabetes educator and/or an endocrinologist in a metropolitan hospital.